Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosite files amended PMA (pre-market approval) for CHF (congestive heart failure) test:

This article was originally published in Clinica

Executive Summary

Biosite Diagnostics has submitted to the US FDA an amendment to its PMA application for its Triage BNP test for congestive heart failure (CHF). The amendment contains data that was requested by an FDA advisory panel, which earlier this year turned down the company's original PMA. "We have submitted data using a control group whose ages closely match those of the population of CHF patients," said the San Diego, California, company. "We have provided more data relevant to female CHF patients and to patients in certain ethnic groups," it added. The test measures B-type natriuretic peptide in whole blood and plasma.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT074801

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel